The HPRA advises healthcare professionals not to retain printed versions of Summary of Product Characteristics (SPC) documents. As these documents are subject to frequent content updates, including changes to safety and dose related information, we recommend that you visit our website as necessary to access the most up-to-date versions. If you have any queries about specific SPCs on our website then please e-mail info@hpra.ie


Targocid 400mg Powder and Solvent for Solution for Injection/infusion or oral solution



Sanofi-Aventis Ireland Limited T/A SANOFIPA0540/021/002

Main Information

Trade NameTargocid 400mg Powder and Solvent for Solution for Injection/infusion or oral solution
Active SubstancesTeicoplanin
Dosage FormPowder and solvent for solution for injection/infusion
Licence HolderSanofi-Aventis Ireland Limited T/A SANOFI
Licence NumberPA0540/021/002

Group Information

ATC CodeJ01XA Glycopeptide antibacterials
J01XA02 teicoplanin

Status

License statusAuthorised
Licence Issued23/02/1990
Legal statusProduct subject to prescription which may not be renewed (A)
Supply StatusSupply through pharmacies only
Advertising StatusAdvertising to healthcare professionals only
Conditions of Licence
Marketing StatusMarketed

Documents

Summary of Product CharacteristicsPDF Version
Package LeafletPDF Version
Public Assessment ReportNo document available
« Back